30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q14 Revenue: K2M

$47.5MM, +18% (U.S. $33.2MM, +12%; ex-U.S. $14.3MM, +35%)

  • U.S. Complex Spine $13.8MM, +6%
  • U.S. Minimally Invasive $5.1MM, +10%
  • U.S. Degenerative $14.2MM, +19%


  • U.S. growth driven by expanding surgeon base; new surgeon revenue ~$7.2MM, partially offset by pricing, decrease in existing customer usage, product mix
  • Ex-U.S. driven by distributor partners in Spain, Denmark and Japan
  • On track to commercialize 5 to 8 products or extension by year-end
  • Launched EVEREST Deformity, EVEREST Minimally Invasive Retractor and submitted filing to FDA for CAPRI corpectomy cage system
  • Launched CAYMAN Minimally Invasive Plate in the U.S., U.K. and Australia
  • Introduced SERENGETI Minimally Invasive Retractor to Japan (largest market ex-U.S.)
  • Received 510(k) clearance for CASPIAN Occipital Anchor (compatible with MESA systems)
  • U.S. Complex Spine now includes procedures performed via MIS techniques that were historically reported in the Minimally Invasive category
  • Hired 100 direct reps in last two years